Isoptin Rr

Verapamil Hydrochloride, the active ingredient in Isoptin Rr, is a calcium channel blocker (non‑dihydropyridine) presented as an unspecified strength/tablet for oral use. It treats hypertension, angina pectoris, and supraventricular tachyarrhythmias in adult patients.

GNH USA supplies Isoptin Rr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Verapamil Hydrochloride is used to manage cardiovascular conditions that involve abnormal heart rhythm or elevated blood pressure.

- Hypertension: reduces systemic blood pressure by decreasing peripheral vascular resistance. - Angina pectoris: relieves chest pain by improving coronary blood flow and lowering myocardial oxygen demand. - Supraventricular tachyarrhythmias (e.g., atrial fibrillation, atrial flutter): helps control heart rate and restore normal rhythm.

Verapamil may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Headache: mild to moderate intensity. - Dizziness: often related to blood‑pressure changes. - Peripheral edema: swelling of the lower limbs.

Serious or Rare Side Effects: - Bradycardia: markedly slow heart rate. - Severe hypotension: sudden drop in blood pressure. - Heart block: impaired electrical conduction. - Hepatic dysfunction: abnormal liver enzyme elevations.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for potential complications.

- Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. - Cardiac function assessment: evaluate for pre‑existing AV block or heart failure. - Drug interactions: review concomitant medications that affect cardiac conduction or CYP metabolism. - Renal/hepatic impairment: use cautiously in patients with severe dysfunction. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture and light.

Verapamil interacts with several medicines; some combinations should be avoided while others require close observation.

Major Interactions (Avoid): - Beta‑blockers: may cause excessive bradycardia or AV block. - Digoxin: increased risk of toxicity due to reduced clearance. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): raise verapamil plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): lower plasma levels, reducing efficacy.

Moderate Interactions (Monitor Closely): - Statins metabolised by CYP3A4 (e.g., simvastatin): increased risk of myopathy. - Diuretics: may enhance hypotensive effect.